Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective

Zdenek Sumnik, Agnieszka Szypowska, Violeta Iotova, Natasa Bratina, Valentino Cherubini, Gun Forsander, Sujata Jali, Joao Felipe Raposo, Gordana Stipančic, Andriani Vazeou, Henk Veeze, Karin Lange, N. Papo, D. Kownatka, Silvia Lion, P. Gerhardsson, T. Kalina, B. Rami-Merhar, J. Svensson, R. HanasM. Knip, M. Witsch, R. Verkauskiene, S. Todorovic, P. Toth-Heyn, M. Ng, J. Pelicand, K. Podolakova, B. Timar, K. Casteels, R. Cordona Hernandez, H. Hoey

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)


Background: Frequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009. Methods: The study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium. Results: We collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU. Conclusions: Although innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement.

Original languageEnglish
JournalPediatric diabetes
Publication statusPublished - 1 Jan 2019


  • children
  • diabetes technology
  • reimbursement
  • type 1 diabetes


Dive into the research topics of 'Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective'. Together they form a unique fingerprint.

Cite this